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Although current thinking has focused on genetic variation between individuals and envi-
ronmental influences as underpinning susceptibility to both autoimmunity and cancer, an
alternative view is that human susceptibility to these diseases is a consequence of the way
the immune system evolved. It is important to remember that the immunological genes
that we inherit and the systems that they control were shaped by the drive for reproduc-
tive success rather than for individual survival. It is our view that human susceptibility to
autoimmunity and cancer is the evolutionarily acceptable side effect of the immune adap-
tations that evolved in early placental mammals to accommodate a fundamental change
in reproductive strategy. Studies of immune function in mammals show that high affinity
antibodies and CD4 memory, along with its regulation, co-evolved with placentation. By
dissection of the immunologically active genes and proteins that evolved to regulate this
step change in the mammalian immune system, clues have emerged that may reveal ways
of de-tuning both effector and regulatory arms of the immune system to abrogate autoim-
mune responses whilst preserving protection against infection. Paradoxically, it appears
that such a detuned and deregulated immune system is much better equipped to mount
anti-tumor immune responses against cancers.
Keywords: CD4T cell, autoimmunity, tolerance mechanisms, cancer, regulation, memory, keyword
INTRODUCTION
In our society today, cancer and autoimmunity are major causes
of suffering and death, and a huge financial burden on health ser-
vices worldwide. The strongest genetic link with autoimmunity is
tomajorhistocompatibility (MHC)class II genes, implicatingCD4
T cells in autoimmune pathogenesis. Less obviously, CD4 T cells
are also implicated in defective immunity to tumors, as CD4 reg-
ulatory T cells (Tregs) limit effector responses to tumor antigens.
Our studies have centered on CD4 immunity and its regula-
tion, and have been informed by the striking observation that the
key features of the CD4 immune system – high affinity antibody
responses,memory, andCD4 regulation – co-evolvedwith placen-
tation in mammals (1–3). A simple comparison of the numbers of
species in different mammalian groups – monotremes, 2; marsu-
pials, ~400; placentals, ~5000 – illustrates the reproductive advan-
tage conferred by placentation. The contribution of the immune
system to this advantage is threefold: the bringing of unborn young
to immunocompetence at birth; protection after birth bymaternal
transfer of high affinity IgG; and reduction in exposure of offspring
to disease epidemics due to memory responses in the community,
the latter two being CD4 T cell dependent functions. Note that the
pressure on the immune defenses due to the physical frailty of the
placental newborn is enormous, as demonstrated by the fact that
even with the immune protections described, mortality is expo-
nentially higher in infants than in adults (4). The high potency of
effector immune responses demanded by placentation carries high
risk of pathological autoimmunity, which has been substantially
addressed by the co-evolution of T regulatory mechanisms. But
because Darwinian selection favors reproductive success rather
than individual survival, the protection of the developing fetus
takes precedence over the risk of personal suffering and even death
in post-reproductive adults. Andwe believe that the less than com-
plete limitation of autoimmunity byT regulation already carries its
own risk, also consequent on the stringent necessity of reproduc-
tive success. Before placentation, protection of the self from effec-
tor responses required tolerance to tissue specific self-antigens;
the evolution of placentation required this tolerance to extend to
placenta- and fetus-specific antigens as well. Additionally,we think
that the intermittent nature of pregnancy fosters the selection of
dominant forms of tolerance (see Evolution of the Placenta – A
New Organ). Our view is supported by two lines of evidence: –
the wide expression of fetus- and placenta-specific antigens by
human cancers in both males and females (5), reflecting selec-
tion of cancer cells that can gain advantage from the immune
regulation protecting the developing embryo and fetally derived
placenta; – recent identification of memory Tregs induced specifi-
cally by fetally derived antigens (6). Although deletional tolerance
no doubt also operates to maintain tolerance to fetally derived
antigens, the particular advantage of dominant tolerance to fetal
antigens expressed in the placental trophoblast is that it could
also confer bystander tolerance to fetal alloantigens at the feto-
maternal interface, to which there is no opportunity for maternal
thymic tolerance, particularly during first time pregnancies before
there is priming to induce Tregs specific for alloantigens (6).
In this article, we start by reviewing the fundamental changes
that occurred in mammals over the last 200 million years
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[see Figure 1 Ref. (7)] and that form the context of the sequen-
tial genetic changes that enabled new immunological structures
and functions to evolve. We then review the evidence that the
resulting “modern” mammalian immune system can be detuned
to give a minimal essential immune system for health: a system
that,without compromising immunity to infection,canboth abro-
gate pathogenic CD4 driven autoimmune responses and augment
anti-tumor immunity.
BRIEF HISTORY OF MAMMALS FROM AN IMMUNOLOGICAL
PERSPECTIVE
Comparative genomics and the fossil record have been used as
a timeline for the evolution of mammals from the common
reptilian ancestor [Figure 1 Ref. (7)]. This timeline highlights
the major physiological changes that emerged: the evolution of
homeothermy, of hair (insulation), and of lactation (an effec-
tive strategy to nourish homeothermic offspring). All mammals,
including the egg laying monotremes, have these characteristics,
which distinguish them from the cold-blooded common ancestor
they share with reptiles and birds.
ORIGINS OF LYMPH NODES
The development of these characteristic mammalian attributes
was accompanied by changes in the immune system,both anatom-
ically and functionally. The most striking gross anatomical change
is the emergence of intra-lymphatic lymphoid aggregates (the
ancestors of lymph nodes) in the common mammalian ances-
tor. All jawed vertebrates have a spleen and lymphoid aggregates
in the mucosal associated lymphoid tissues, but only mammals
have lymphoid structures that are intra-lymphatic as opposed to
lymphatic-associated. In chickens, lymphoid aggregates are found
in the wall but not the lumen of lymphatics (8), which is a similar
arrangement to the so called isolated lymphoid follicles (ILFs)
found at mucosal sites in all vertebrates, and associated with
FIGURE 1 | Emergence of traits along the mammalian lineage.
Amniotes split into the sauropsids (leading to birds and reptiles) and
synapsids (leading to mammal-like reptiles). These small early
mammals developed hair, homeothermy, and lactation (red lines).
Monotremes diverged from the therian mammal lineage ~166Myr ago
and developed a unique suit of character (dark-red text). Therian
mammals with common characters split into marsupials and eutherians
around 148Myr ago (dark-red text). Geological eras and periods with
relative times (million years ago) are indicated on the left. Mammal
lineages are in red; diapsid reptiles, shown as archosaurs (birds,
crocodilians, and dinosaurs), are in blue; and lepidosaurs (snakes,
lizards, and relatives) are in green.
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but not inside lymphatics (e.g., the lacteals in the gut). In con-
trast, vascularized intra-lymphatic ILF-like structures are found
in both of the extant monotremes (9, 10). Why did these intra-
lymphatic structures, which are the precursors of mammalian
lymph nodes, evolve? Possible explanations in our view are linked
to the evolution of homeothermy in mammals, with the conse-
quent increased demand for nutrients. The mucosal system of
mammals has a much more extensive surface area for absorption
of food than reptiles, and consequently has increased exposure
to bacteria, both commensal and non-commensal, in the gut.
One view therefore, is that these intra-lymphatic lymphoid struc-
tures evolved in the mesentery of the gut as a “firewall” to block
the entry of gut bacteria into the systemic circulation (11). In
any case, comparative genomics supports the view that intra-
lymphatic lymphoid structures evolved in the common mam-
malian ancestor, as the L-selectin gene (SELL) first appears in
monotremes (www.ensembl.org). This molecule occurs on lym-
phocytes and directs their exit from blood vessels into lymphatics
(as lymph nodes are essentially intra-lymphatic structures), and is
not present in reptiles or birds, which however do have genes for
the inflammatory selectins present on endothelium,E-(SELE), and
P-selectin (SELP). SELE and SELP are chromosomally co-located
in mammals with L-selectin, indicating that SELL is likely to have
arisen by gene duplication in the common mammalian ancestor.
Microscopically, the ILFs found inside the lymphatics of
monotremes contain B cell germinal center (GC)-like structures
with follicular CD4 T cells (10), but they do not contribute to
affinity maturation of the B cell response or to memory; sec-
ondary antibody responses in monotremes are very similar to
primary ones (2). In the absence of a link to affinity matura-
tion, it seems probable that these GC-like inclusions mediated
the diversification of the B cell repertoire, after the fashion of the
GC-like structures seen to develop in the Bursa of Fabricius in
chickens, where the B cell repertoire is diversified by activation
induced cytosine deaminase (AID)-dependent gene conversion of
immunoglobulin variable region genes (12). In placental animals
like sheep, primary diversification of the B cell repertoire through
gene conversion and somatic hypermutation also occurs in the
gut associated lymphoid tissues (13), so it is quite plausible that
this is the function first appearing inside intra-lymphatic nod-
ules in monotremes. Orthologs of IgE and IgG also evolved in the
common mammalian ancestor; in monotremes (14), unlike pla-
cental animals, switched immunoglobulin isotypes are produced
in primary immune responses, and it is possible that the sites of
AID-dependent class switching, to not only IgE and IgG, but also
IgA, are the intra-lymphatic ILFs.
IgA CONTROL OF ANTI-INFLAMMATORY AND RESPONSES TO GUT
MICROBIOTA
IgA is the most abundant immunoglobulin, and secreted IgA is
the main immunoglobulin at mucosal surfaces. Orthologs of IgA
are present in reptiles, birds, and mammals but not amphibians
and fish, indicating that this immunoglobulin class evolved in
the common amniotic ancestor of land animals. The evolution
of the amniotic egg was critical to the capacity of vertebrates to
colonize non-aquatic habitats, as it freed their reproduction from
the dependency on access to water retained by amphibian species.
However, terrestrial habitats brought new challenges in the form
of different food sources and different microbiota colonizing the
gut. In this context, the anti-inflammatory properties of IgA are
likely to have been crucial. Tsuji et al. (15) present several pieces of
evidence pointing to the importance of IgA in maintaining a nor-
mal gut flora. AID-deficient mice developed abnormal gut flora,
which was associated with impaired switching to IgA in ILFs in the
mucosa. This IgA-dependent class switching was shown to be T
cell independent, but dependent onAID expression in ILFGC-like
structures.
ORIGIN OF CD4 IMMUNITY
Modern mammals share a 450-Myr-old common ancestor with
cartilaginous fish, and indeed all jawed vertebrates have RAG-
dependent adaptive immune systems. However, recent sequencing
of the elephant shark genomehas revealed no evidence for theCD4
gene, and indeed no evidence of either FoxP3, the gene linked to
evolution of CD4 regulation (16), or ROR-gamma (RORc), the
transcription factor required for the development of Th17 CD4
T cells (17). This suggests that CD4 T cells were not part of the
ancestral RAG-dependent adaptive immune system, but evolved
later. Recent data have implicated both CD4 Th17 cells and Tregs
in IgA immunity.
FoxP3+ AND Th17 CD4 T CELLS ARE INVOLVED IN IgA PRODUCTION IN
THE GUT
The FoxP3 gene is highly conserved in all placental mammals
(www.ensembl.org). Given that members of the FoxP gene fam-
ily are consistently highly conserved across all animal groups,
this would not be surprising, except that by comparison, FoxP3
orthologs in marsupials, marsupials, reptiles, monotremes, fish,
and amphibians show much reduced conservation. The step gain
in conservation of FoxP3 in placental mammals is consistent with
a gain of function specific to placentation (18). Similarly, IL17a,
the principle IL17 cytokine secreted by Th17 T cells, is exclusive
to mammalian genomes, and therefore evolved in the common
mammalian ancestor.
The conventional view of FoxP3+ Tregs is that their primary
role is to suppress ormodulate CD4 dependent immune responses
(19), but there is evidence that they also function in the T cell
dependent switching to IgA in the gut: Foxp3 expressingTregswere
potent inducers of IgA after transfer in T cell deficient mice (20);
Tregs were found to be importantmediators of induction of IgA to
flagellin, a molecule common to commensal and pathogenic bac-
teria (21). The latter result raised the very interesting idea that a key
function of Tregs is to promote the generation of IgA antibodies to
commensal bacteria in the gut, so maintaining homeostasis of gut
microbiota and preventing inappropriate inflammatory immune
responses. A possible role for the ancestral FoxP3-dependent Tregs
could therefore be to moderate immune responses to commensal
bacteria by effectively providing help for B cells.
This suggestion is somewhat controversial, as recent studies
have implicatedTh17 cells rather thanTregs in the inductionof IgA
in the gut (22, 23). Cao et al. implicated the mammalian specific
cytokine IL17a in the production of IgA to flagellin. The available
data are however not necessarily contradictory, as in humans at
least a significant fraction of Tregs isolated from mucosal surfaces
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co-express FoxP3 and RORgt, the key Th17 transcription factor
(24), in addition to producing IL17a. A scenario compatible with
the evidence is that there was co-evolution of Th17 and FoxP3+
T cells in the common mammalian ancestor, at least in part to
promote IgA antibody production in the gut, and in any case to
act synergistically to promote integrity at mucosal surfaces.
EVOLUTION OF HIGH AFFINITY ANTIBODIES AND MEMORY IN THE
COMMON PLACENTAL ANCESTOR
As discussed earlier (see “Origins of Lymph Nodes” above),
despite having intra-lymphatic lymphoid follicles containing GCs,
monotremes do not make high affinity antibody responses or
demonstrate CD4memory (2, 9, 10). They do not have true lymph
nodes with segregated B and T cell areas, but these structures
evolved in the common placental ancestor; all marsupials and pla-
cental mammals have lymph nodes, and demonstrate the capacity
to make high affinity antibodies and memory (1, 3, 25, 26). These
advances are linked to the evolution of new genes, notably the
lymphotoxin breceptor (LTbR) and its ligands, which are not only
essential for lymph node development but also for making high
affinity antibodies and memory.
LYMPHOID TISSUE INDUCER CELLS: Rorg DEPENDENT, AND LINKED
WITH BOTH LYMPH NODE AND CD4 MEMORY DEVELOPMENT
ReinaMebius was the first to characterize murine lymphoid tissue
inducer cells (LTi) (27). Their function in the development of lym-
phoid tissues was revealed when it was found thatmice deficient in
the orphan retinoic acid receptor gamma (RORg) lacked both this
CD4+CD3  LTi population and lymphnodes (28,29). These stud-
ies link LTi unequivocally with the development of lymph nodes,
cryptopatches, and ILFs through their expression of the tumor
necrosis superfamily members (TNFSF) for the lymphotoxin beta
receptor (LTbR), LTa1b2 (30), and TRANCE (31); more recent
studies have also shown that LTi are rich sources of the cytokine,
interleukin 22 (IL22) (32), which is associated with the promotion
of defenses at epithelial sites (33–35). This would permit the LTi
a function in the promotion of innate immunity that is distinct
from the induction of lymphoid tissues.
Additionally, our work has shown that LTi persist in adult
lymphoid tissues in bothmouse (36) andman (37), but are distin-
guished from the neonatal population by their expression of high
levels of OX40-ligand (OX40L)(TNFSF4) (36, 37) and in mouse,
CD30L(TNFSF8) (36). Our studies have found that CD4 T cell
memory function is highly dependent on signaling through both
OX40 and CD30 (38), suggesting additional roles for LTi in the
mediation of adaptive CD4 dependent immune responses.
IMPORTANCE OF THE IMMUNE CONTRIBUTION TO PLACENTATION
It is difficult to refute the significance of the co-evolution of high
affinity antibodies and lymph nodes with placentation. Zinker-
nagel (39) takes the view thatmemory and high affinity antibodies
are chiefly relevant because they protect offspring via maternal
transfer of high affinity antibodies, and theway inwhich immuno-
logical functions have evolved during placentation broadly sup-
ports his perception.We know that orthologs of IgG first appeared
in the common mammalian ancestor because monotremes have
them (14). The neonatal Fc receptor (FCGRT), however, which
is the gene that enables the crucial transfer of IgG from mother
to offspring as well prolonging the beneficial effects of IgG by
increasing its half-life (40), is only present in marsupial and
placental genomes. Studies of human infant mortality to most
common infections show an exponential decline with the age (4)
with exception of the first year of life where transfer of mater-
nal IgG plays a crucial role in infant survival through protective
immunity. Indeed in many placental animals failure to transfer
maternal IgG is fatal. Comparative genomics therefore supports
the idea that the development of the capacity to make high affinity
antibodies and transfer them to offspring is an integral compo-
nent of the evolution of a fundamental change in reproductive
strategy.
CO-EVOLUTION OF HIGH AFFINITY ANTIBODIES WITH
FoxP3-DEPENDENT REGULATION
In placentals, GCs in B follicles are the locations where T cell
dependent B cell selection drives the generation of high affinity
antibodies (41), but there must exist mechanisms to edit self-
reactive GC B cells that acquire self-reactivity. This can occur
because self-proteins can be inadvertently conjugated to foreign
proteins (e.g., apoptotic virally infected cells), and therefore GC B
cells that acquire self-reactivity by chance have the capacity to get
help from GC follicular T helper cells. Indeed, it is very common
in viral infections in humans to get transient low affinity autoanti-
body production, but this does not usually go on to generate high
affinity class switched autoantibodies.
Recent studies have shown that Tregs are also present in normal
GC (42, 43) and the fact that high affinity IgG autoantibodies to
a wide variety of tissue-restricted antigens are found in FoxP3-
deficient mice indicates that Tregs must be pivotal in preventing
the generation of these autoantibodies. Although it is by nomeans
clear how Tregs in GC prevent autoantibodies being generated,
there is better evidence for how self-specific Tregs are selected.
Recent work has shown the critical role of the thymic medulla in
the selection of thymic derived regulatory but not conventional
T cells (44). The gene AIRE, expressed in the thymic medulla,
controls the expression of many tissue-restricted antigens (45,
46). Intrathymic deletion of self-specific T cells is substantially
AIRE-dependent (47), but the process of selection against tissue-
restricted antigens is also a plausible mechanism by which Tregs
specific for self-antigen could be selected in thymus and go on to
exert their effects in the periphery.
When considering the origin of the requirement for regulation
of immune effectors, it is clear that, in the absence of memory
and high affinity IgG, the consequences for monotremes of inad-
vertently making anti-self antibody responses are mild; all their
antibodies are low-titer, low affinity, and transiently produced, so
one would surmise that the requirement for regulation is limited.
Substantial changes in the FoxP3 gene occurred during the evo-
lution of placentation (18), and the relevance of this is further
demonstrated by the failure of regulation in placental animals
having mutant forms of FoxP3 lacking critical domains (18).
EVOLUTION OF THE PLACENTA – A NEW ORGAN
The major advantage of placentation over oviparous forms of
reproduction is that it greatly increases the chances of reproductive
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success by prolonging the parental protection of the developing
offspring, including increasing the chance of surviving infection
courtesy of a more mature immune system, initially supported
by high affinity maternal IgG antibodies. A recent detailed study
of placental fossils combined with comparative genomic data
concluded that all modern placentals (Eutherians) are derived
from a common placental ancestor that survived the mass extinc-
tion 65Myr ago that eliminated terrestrial dinosaurs (48). Infer-
ences from this study are that this common Eutherian ancestor
had a hemochorial placenta with the fetal and maternal blood
circulations in intimate contact. Marsupials represent an inter-
mediate step toward this state; they are born very immature
and before their immune system develops, but nevertheless get
the benefit of protection from predation by ex utero occupa-
tion of the maternal pouch, where lactation provides the added
advantage of maternally transferred antibodies. Marsupials have
a yolk sac (Metatherian) placenta, which is simple and relatively
impervious to feto-maternal exchange, thus dodging the issue of
maternal recognition of fetal and placental antigens. In Euther-
ian mammals, however, the placenta is fully adapted to cope
with a fetus that develops to maturity. There are many new
genes that arose during the evolution of placentation to pro-
gram the development of the placenta (a fetally derived organ)
(49), and in addition there are genes essential for survival of
the fetus itself in utero. The common ancestor of marsupials
and placentals, in which these new genes were evolving, had
the capacity to make high affinity antibodies; for the hemocho-
rial placenta with its proximity of maternal and fetal circula-
tions, the selective drive for immune regulation capable of pro-
tecting the fetus from rejection by its own mother was clearly
decisive.
Two facts need to be remembered concerning the placenta:
- Morphologically it is very diverse in different classes of mam-
mal, reflecting the strong evolutionary pressure for mammals
with different lifestyles to adapt reproductively to different exter-
nal conditions. This is reflected in the evolution of new genes
and new gene families in different mammalian classes and is
particularly evident on the X chromosome, where many of the
placental genes are concentrated and which also evolved from
an autosomal chromosome in placentals (5).
- Placentation is an intermittent phenomenon, so maintaining
T cell tolerance to the rapidly evolving new proteins that are
not present in mammalian females post birth, but to which T
cell tolerance will be essential if they are to be reproductively
successful is a real challenge. From an evolutionary perspec-
tive, it is therefore not difficult to understand why the adap-
tation to placentation might select for mechanisms of dom-
inant tolerance mediated by Tregs, i.e., where Tregs specific
for some of the newly evolving placental and fetal-restricted
antigens could suppress maternal effector responses against
them, whereas other, maybe less abundant or otherwise less
conspicuous, neo-antigens would escape without significant
Treg reaction. A further point is that this dominant regula-
tion against thymic expressed placental antigens expressed at
the feto-maternal interface could also suppress allorecognition
of paternal MHC.
EVOLVING MATERNAL TOLERANCE TO FETUS AND PLACENTA
Because it seems very likely that the problem of maternal toler-
ance to fetal and placental proteins had already been solved in the
common eutherian placental ancestor, we looked for genetic dif-
ferences between marsupials and eutherian placental mammals in
the genes linked to induction and selection of Tregs in mTECs in
thymus. The T cell costimulatory molecule CD28 is vital for Treg
selection (50), and CD28 ligands, particularly CD80, are expressed
on AIRE+ mTECs. In all eutherian placental genomes examined,
AIRE, the gene associated with selection of antigen-specific Tregs
is chromosomally co-locatedwith theCD28paralog, ICOS-ligand.
The ICOS signaling pathway is crucial for the generation of high
affinity antibodies inGCs (51); particularly pertinent to the genetic
association between ICOSL and AIRE, it is also required for the
effective Treg suppressive function (52). Thus the ICOS gene is a
pivot between high affinity antibody production and effective Treg
function against immune responses to self, raising the very inter-
esting possibility that the expression of this gene facilitated the
selection of self-antigen-specific Tregs found in GCs (43), which
then edit self-reactive B cells in GCs driven by ICOS signaling
interactions.
The comparative genomics of these interactions is instructive.
In all marsupial genomes examined, AIRE and ICOSL are not co-
located, but are on separate chromosomes, as is also the case in
reptiles and birds. Maybe the genetic translocation that brought
AIRE and ICOSL together in the common placental ancestor also
mediated the co-expression of AIRE with ICOSL on mTECs. We
think that this co-expression was likely to have facilitated devel-
opment of the process of selecting antigen-specific Tregs, and see
it as an illustration of how mutually beneficial processes could
serve as selective advantages for one another: here the genetic
mechanism for improving antibody affinity (ICOS signaling) co-
evolved with the genetic mechanism maintaining tolerance to self
(selection of antigen-specific Tregs via AIRE) to modify the gener-
ation of high affinity antibodies to tissue-restricted antigens – in
this case those expressed in the placenta and fetus. This allows
antibodies to pathogens to be transferred to offspring, protect-
ing them from infection without causing autoimmunity, which is
a genuine risk, as there are many examples of passive maternal
transfer of IgG autoantibodies causing disease in the neonate. In
FoxP3KOOX40CD30KO mice where not only affinity maturation,
but also autoantibody production is impaired, the requirement for
Tregs is obviated.
Other studies have linked Tregs specifically with the main-
tenance of allotolerance at the feto-maternal interface (53–
55). However, our data from the FoxP3KOOX40CD30KO mice
do not support this interpretation. Our data show that
FoxP3KOOX40CD30KO mice are fully able to reject allografts
(data not shown) but we found no evidence that female
FoxP3KOOX40CD30KO mice rejected allogeneic fetuses. Recent
data suggest that immunosuppression in the fetal circulation need
not be cell-mediated and implicates the expression of arginase by
fetal blood cells (56). Because the fetus is normally sterile, such a
global suppression of immune responses in the fetal circulation,
and therefore by definition also at the fetal/maternal interface in
the placenta, is in our view, a potential mechanism to prevent
maternal lymphocytes that enter the fetal circulation inducing
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rejection. The selective expression of immunosuppressive arginase
in the fetal red blood cells in the fetal circulation also helps to
explain why lymphocytes in the maternal compartment are still
able to respond. For example, although in pregnancy there is sus-
ceptibility to some infections, notably influenza, pregnant women
make good antibody responses after vaccination (57). We think,
therefore that the requirement for regulation in the form of Tregs
is more relevant in the context of the mother, to allow antibody
responses in particular to foreign proteins derived from infectious
pathogens (maternal IgG then passively protects offspring after
birth) to go ahead, but to head off responses to fetal or placental
antigens that enter the maternal circulation.
MINIMAL IMMUNE SYSTEM FOR MAMMALIAN HEALTH
Our studies had shown that the TNF-family members, OX40
and CD30-ligand were crucial for the development of high affin-
ity antibodies and memory (38). Although CD30 and its ligand
were present in the common amniotic ancestor, true orthologs of
OX40-ligand, which plays the dominant role in both affinity mat-
uration and memory, are only present in the mammalian lineage
(www.ensembl.org). To ask the question of whether CD4 regula-
tion and memory could have co-evolved in the common placental
ancestor we reasoned that mice deficient in FoxP3 (no Tregs) and
also deficient in OX40 and CD30 (no high affinity antibodies and
memory) would mimic at least to some extent the immune sys-
tem of the commonmammalian ancestral immune system seen in
monotremes, and would not exhibit autoimmunity. This was the
case (58).
Our mice are interesting in several respects. First, the gener-
ation of autoantibodies is abrogated in these mice and they fail
to develop the widespread autoimmunity seen in mice and men.
The development of FoxP3KO disease is CD4 dependent (19) but
the FoxP3KOCD30OX40KO mice do not behave as CD4-deficient
as they do generate GCs and switched antibody not dissimilar to
that observed inmonotreme responses. Furthermore, they control
many herpes viruses (CD8 immunity is preserved) as well as bac-
teria. The behavior of the immune responses in the CD30OX40KO
mice is mirrored in a single reported case of OX40-deficiency in
humans (59). Although the individual did suffer from Kaposi’s
sarcoma, she controlled commonHerpes virus infections, and was
not unduly susceptible to bacterial infections, despite the absence
of recall CD4 memory responses.
If one accepts Zinkernagel’s view that the development of
memory and high affinity antibodies is a strategy optimized for
reproductive success rather than individual survival, then the
Foxp3KOOX40CD30KO immune system in our view represents
the “minimal immune system for health,” the necessary and suf-
ficient platform that had evolved in the common mammalian
ancestor before the evolution of high affinity antibodies and
memory induced a compromise in the form of susceptibility to
autoimmunity.
HUMAN AUTOIMMUNITY AND BLOCKADE OF OX40 AND CD30
SIGNALING PATHWAYS
In human genome wide association studies (GWAS) class II poly-
morphisms are the strongest genetic link, highlighting the role of
CD4 T cells in immunopathology, either due to failure to select
antigen-specific Tregs in thymus that subsequently protect, or
because CD4 effector T cells drive pathology. The significance
of the Foxp3KOOX40CD30KO mice with a global defect in Tregs
is that it suggests that blocking OX40 alone, or in combination
with CD30, would be very effective treatment for wide number
of CD4 driven autoimmune diseases without rendering patients
susceptible to infection. This is further supported by evidence that
shows that FoxP3KO disease can also be blocked by co-injection of
antibodies that block OX40 and CD30 signaling pathways (58).
CANCERS MIMIC THE IMMUNE EVASION STRATEGY OF PREGNANCY
The link between placentation and cancer is hardly new (60).
From our perspective, a substantial role for dominant FoxP3-
dependent regulation was to facilitate the growth of the fetus
and placenta, both expressing many neo-antigens, while at the
same time being permissive particularly for the generation of anti-
bodies to pathogens. Recent whole exome sequencing of human
cancers has also revealed their enormous heterogeneity (61).
Although in theory this should render tumors immunogenic to
the CD8 immune system in particular, it is clear that dominant
Treg tolerance is a major stumbling block to the development
of effective anti-tumor immune responses if Tregs specific for
self-antigens can suppress immune responses to tumor-specific
antigens.
Two gene examples illustrate the point. The first is the gene
alpha-fetoprotein (AFP), the fetal albumin adapted to in utero sur-
vival, an autosomal gene. The second is the gene PLAC1 expressed
in the trophoblast of the placenta of all placental animals, and
exclusive to placental animals. Both of these genes are part of the
genetic adaption toplacental reproduction,but they are alsowidely
expressed in human cancers. This fact suggests that the suppressive
effect of fetal and placental antigens on immune responses might
have led to the success of cancers that express them. As stated ear-
lier, medullary epithelium in thymus (mTEC) is crucial for the
selection of Tregs but not conventional T cells (44). Both PLAC1
and AFP are over-expressed in mTECs [compared to cortical
epithelium (cTECs)] (our own data and also www.immgen.org),
so it is quite plausible that Tregs specific for these proteins could be
selected in thymus. Support for this type of dominant tolerance
preventing immune responses to cancer is also provided by the
following study (62).
In this study, T cell receptors (TCRs) from tumor infiltrating
Tregs found in a murine model of prostate cancer were cloned.
TCR transgenic mice positively selected Tregs in thymus in both
male and femalemice, indicating that theywere not tumor-specific
Tregs, and as they were found in female mice, were not selected in
prostate! Their mTEC thymic derivation was further supported by
the observation that selection was dependent on AIRE, the gene
that controls expression of many tissue-restricted antigens in the
thymus (45).
DE-TUNING THE IMMUNE SYSTEM TO UNBLOCK CD8 ANTI-CANCER
IMMUNE RESPONSES
Strategies that suppress Treg function [CTLA4 blockade (63, 64)
and PD-1 (65)] have been effective in releasing CD8 anti-tumor
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immune responses, particularly when used in combination (66).
Because Tregs suppress CD4 driven autoimmunity, autoimmunity
is a major cause of morbidity and mortality in these treatments.
Like Foxp3KO mice, CTLA4KO mice die of CD4 driven autoim-
munity (67) so in reality CTLA4 blockade can only be partial in
human patients.
However, our studies in FoxP3KOOX40CD30KO mice sug-
gest that that CD4 mediated immunity can be obviated in
FoxP3KO without seriously compromising autoimmunity. To test
whether thesemicewere capable of mounting anti-tumor immune
responses we used the well establishedmurine melanoma line B16
(68). This tumor grows rapidly in syngeneic B16 mice but tumor
growth is virtually abrogated in FoxP3KOOX40CD30KO mice (our
unpublished observations). To us this observation has potential
important implications for the treatment of human cancers as it
offers the option of permitting effectiveCD8 anti-tumor responses
while preventing the unpleasant CD4 driven autoimmune side
effects.
SUMMARY
In this perspective we outline a strategy for attenuating CD4
driven immunopathology by blockade of the TNF super family
members, OX40L (in particular), and CD30L (synergistic with
OX40L). Studies of immune function in mice deficient in OX40
and CD30 reveal that although CD4 immunity is reduced, defi-
cient mice are able to deal with the common viral and bacterial
infections that can be associated with conventional immunosup-
pressive strategies. We suggest that antibodies that block these
pathwaysmayhave therapeutic benefit inhumanautoimmunedis-
eases mediated by CD4 T cells without compromising resistance
to infection.
Recent work has shown that blockade of regulatory T cell
function with CTLA4-blocking antibodies has revealed impressive
“repressed” CD8 immune responses to neo-antigens expressed by
human cancers, particular melanoma, but also some other solid
tumors. However, this has been at the expense of CD4 driven
autoimmunity that can have considerable morbidity and even
mortality. Our work indicates that in the absence of OX40 and
CD30, FoxP3-dependent Tregs are dispensable, and mice defi-
cient in OX40, CD30, and FoxP3mount excellent CD8-dependent
anti-tumor immune responses.
As stated above, it is our view that human susceptibility to
autoimmunity and cancer are the evolutionarily acceptable side
effects of the immune adaptations that evolved in early placental
mammals to accommodate a fundamental change in reproductive
strategy, and by reversing this process, a detuned and deregulated
immune system is much better equipped to mount anti-tumor
immune responses against cancers but is also resistant to chronic
CD4 driven autoimmune disease.
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